SWP
RGLS

Stratos Wealth Partners’s Regulus Therapeutics RGLS Stock Holding History

Stratos Wealth Partners’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-33
Closed -$3K – 2223
2018
Q1 		$3K Buy
+33
New +$4.42K ﹤0.01% 2773

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Stratos Wealth Partners's RGLS Position: Q2 2018 in Review

Stratos Wealth Partners sold out of Regulus Therapeutics (RGLS) in Q2 2018, closing a stake of 33 shares — an estimated $3K sold.

Stratos Wealth Partners first reported a position in RGLS in Q1 2018 and held it in 1 quarter. The position peaked at $3K in Q1 2018. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2018.

  • Stratos Wealth Partners reported no remaining Regulus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 33 Regulus Therapeutics shares in Q2 2018, an estimated $3K.
  • Stratos Wealth Partners first reported a position in Regulus Therapeutics in Q1 2018 and held it in 1 quarter.
  • Stratos Wealth Partners's Regulus Therapeutics position peaked at $3K in Q1 2018.
  • 46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2018.

Based on Stratos Wealth Partners's 13F filing for Q2 2018, filed 13 Aug 2018.